Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Our main analysis focused on the immediate acute effects of fluoroquinolones. Therefore, as is usually done, we excluded patients exposed during the intermediate risk period. Because the intermediate risk period is not associated with an increased risk, this exclusion is unlikely to have affected the odds ratio. Individuals with a fluoroquinolone prescription during the 10 days preceding retinal detachment (RD) and exposed during the intermediate risk period (ie, during the 50 prior days) were not considered exposed during the risk period. Consistently, individuals with 2 fluoroquinolone prescriptions dispensed within 50 days in the control period were not considered exposed either.
Raguideau F, Dray-Spira R, Zureik M. Oral Fluoroquinolone Use and Retinal Detachment—Reply. JAMA Ophthalmol. 2016;134(12):1448–1449. doi:10.1001/jamaophthalmol.2016.3479
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: